TY - JOUR
T1 - Low rates of both lipid-lowering therapy use and achievement of low-density lipoprotein cholesterol targets in individuals at high-risk for cardiovascular disease across Europe
AU - Halcox, Julian P.
AU - Tubach, Florence
AU - Lopez-Garcia, Esther
AU - De Backer, Guy
AU - Borghi, Claudio
AU - Dallongeville, Jean
AU - Guallar, Eliseo
AU - Medina, Jesús
AU - Perk, Joep
AU - Sazova, Ogün
AU - Sweet, Stephen
AU - Roy, Carine
AU - Banegas, José R.
AU - Rodriguez-Artalejo, Fernando
N1 - Funding Information:
The authors have the following interests. Julian P. Halcox and Jean Dallongeville have received speaker and consulting fees from AstraZeneca. Florence Tubach and Eliseo Guallar have received research funding from AstraZeneca. Stephen Sweet is an employee of Oxford PharmaGenesis Ltd, which has received funding from AstraZeneca. Jesús Medina and Ogün Sazova are employees of AstraZeneca. The EURIKA study was funded by a commercial source (AstraZeneca). Writing support was provided by Oxford PharmaGenesis Ltd, Oxford, UK, and was funded by AstraZeneca. The rest of the authors declare that they have no competing interests. There are no patents, products in development or marketed products to declare. This does not alter the authors′ adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.
Publisher Copyright:
© 2015 Halcox et al.
PY - 2015/2/18
Y1 - 2015/2/18
N2 - Aims: To analyse the treatment and control of dyslipidaemia in patients at high and very high cardiovascular risk being treated for the primary prevention of cardiovascular disease (CVD) in Europe. Methods and Results: Data were assessed from the European Study on Cardiovascular Risk Prevention and Management in Usual Daily Practice (EURIKA, ClinicalTrials.gov identifier: NCT00882336), which included a randomly sampled population of primary CVD prevention patients from 12 European countries (n = 7641). Patients' 10-year risk of CVD-related mortality was calculated using the Systematic Coronary Risk Evaluation (SCORE) algorithm, identifying 5019 patients at high cardiovascular risk (SCORE ≥5% and/or receiving lipid-lowering therapy), and 2970 patients at very high cardiovascular risk (SCORE ≥10% or with diabetes mellitus). Among high-risk individuals, 65.3% were receiving lipid-lowering therapy, and 61.3% of treated patients had uncontrolled low-density lipoprotein cholesterol (LDL-C) levels (≥2.5 mmol/L). For very-high-risk patients (uncontrolled LDL-C levels defined as ≥1.8 mmol/L) these figures were 49.5% and 82.9%, respectively. Excess 10-year risk of CVD-related mortality (according to SCORE) attributable to lack of control of dyslipidaemia was estimated to be 0.72%and 1.61% among high-risk and very-high-risk patients, respectively. Among high-risk individuals with uncontrolled LDL-C levels, only 8.7% were receiving a high-intensity statin (atorvastatin ≥40 mg/day or rosuvastatin ≥20 mg/day). Among veryhighrisk patients, this figure was 8.4%. Conclusions: There is a considerable opportunity for improvement in rates of lipid-lowering therapy use and achievement of lipid-level targets in high-risk and very-high-risk patients being treated for primary CVD prevention in Europe.
AB - Aims: To analyse the treatment and control of dyslipidaemia in patients at high and very high cardiovascular risk being treated for the primary prevention of cardiovascular disease (CVD) in Europe. Methods and Results: Data were assessed from the European Study on Cardiovascular Risk Prevention and Management in Usual Daily Practice (EURIKA, ClinicalTrials.gov identifier: NCT00882336), which included a randomly sampled population of primary CVD prevention patients from 12 European countries (n = 7641). Patients' 10-year risk of CVD-related mortality was calculated using the Systematic Coronary Risk Evaluation (SCORE) algorithm, identifying 5019 patients at high cardiovascular risk (SCORE ≥5% and/or receiving lipid-lowering therapy), and 2970 patients at very high cardiovascular risk (SCORE ≥10% or with diabetes mellitus). Among high-risk individuals, 65.3% were receiving lipid-lowering therapy, and 61.3% of treated patients had uncontrolled low-density lipoprotein cholesterol (LDL-C) levels (≥2.5 mmol/L). For very-high-risk patients (uncontrolled LDL-C levels defined as ≥1.8 mmol/L) these figures were 49.5% and 82.9%, respectively. Excess 10-year risk of CVD-related mortality (according to SCORE) attributable to lack of control of dyslipidaemia was estimated to be 0.72%and 1.61% among high-risk and very-high-risk patients, respectively. Among high-risk individuals with uncontrolled LDL-C levels, only 8.7% were receiving a high-intensity statin (atorvastatin ≥40 mg/day or rosuvastatin ≥20 mg/day). Among veryhighrisk patients, this figure was 8.4%. Conclusions: There is a considerable opportunity for improvement in rates of lipid-lowering therapy use and achievement of lipid-level targets in high-risk and very-high-risk patients being treated for primary CVD prevention in Europe.
UR - http://www.scopus.com/inward/record.url?scp=84923285444&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84923285444&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0115270
DO - 10.1371/journal.pone.0115270
M3 - Article
C2 - 25692692
AN - SCOPUS:84923285444
SN - 1932-6203
VL - 10
JO - PloS one
JF - PloS one
IS - 2
M1 - e0115270
ER -